PROFUSA INC

Company Overview

Profusa, Inc. became a public company through a merger with NorthView Holdings, a blank‑check SPAC, with the merger consummated post‑period (closed July 11, 2025 per filings). The pre‑transaction structure featured heavy SPAC dynamics: large redemptions that drained the trust, Nasdaq delisting and OTC trading, sponsor working‑capital convertible notes, and up to 3,875,000 contingent earnout shares tied to stock‑price, revenue and a Tasly JV funding milestone. Financial disclosures show extreme mark‑to‑market volatility from warrants and convertible instruments, limited cash on hand, deferred closing fees and repeated amendments to earnout and financing terms, leaving near‑term liquidity and earnout achievement as dominant company risks.

Executive Compensation Practices

Compensation is likely to be equity‑heavy and milestone‑driven given Profusa’s medical‑device/med‑tech profile and the SPAC transaction structure: expect base pay plus stock awards, option grants and significant contingent/earnout shares tied to stock price, revenue, JV funding and development/commercial milestones (including regulatory or clinical progress). The SPAC phase and low cash balances mean management and sponsors have relied on convertible promissory notes and deferred fees, so short‑term cash compensation may be modest and supplemented by conversion mechanics or post‑closing equity. Because earnouts and stock‑price thresholds materially affect payouts, executive incentives will be sensitive to financing events, PIPE closings, dilution from warrant/note conversions, and the timing of commercial or regulatory milestones.

Insider Trading Considerations

Watch for concentrated and timing‑sensitive insider activity: conversions of sponsor notes, exercises of founders’ shares, and sales/executions tied to earnout thresholds can create clustered insider transactions around financing and amendment events. Pre‑closing delisting and OTC liquidity constraints historically limited orderly selling and can prompt insider sales for liquidity rather than negative signal; post‑close, low cash and deferred obligations increase the probability of insider sales to cover tax or personal liquidity needs. Regulatory and governance constraints are salient — Section 16 reporting, Rule 10b5‑1 plans, Nasdaq/SOX disclosure obligations, and strict blackout periods around FDA/regulatory, clinical and material contract/earnout announcements — any trades by insiders around those events warrant heightened scrutiny given the company’s high information sensitivity and the large value swings from convertible/warrant remeasurements.